Partners Mylan NV and Theravance Biopharma Inc. say they will submit their nebulized once-daily LAMA respiratory drug revefenacin for regulatory approval after receiving good Phase III safety and tolerability data for the long-acting muscarinic antagonist (LAMA) in treating chronic obstructive pulmonary disease (COPD).
The duo, which have a strategic collaboration to develop and commercialize revefenacin products for COPD and other respiratory diseases, said...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)